Adults 18 to 80, any sex, with Pyoderma Gangrenosum. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Adverse Events and Clinically Significant (CS) Safety MeasurementsSecondary· Up to approximately 12 weeks
Safety was assessed by monitoring and recording all adverse events, clinical laboratory tests (including hematology, serum chemistry, coagulation, and urinalysis), physical and neurological examinations, vital sign measurements, and 12-lead electrocardiograms. The number of participants with adverse events and CS safety measures have been reported.
Group
Value
95% CI
APD334
2
APD334
0
APD334
0
APD334
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to approximately 12 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03155932 — Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
· Phase 2
· terminated
NCT03139032 — Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manif
· Phase 2
· terminated
Other recruiting trials for Pyoderma Gangrenosum
Currently open trials in the same condition.
NCT06624670 — A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
· Phase 3
· recruiting
NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
· Phase 2
· recruiting
Other Arena Pharmaceuticals trials
Trials by the same sponsor.
NCT04655599 — Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
· Phase 1
· terminated
NCT03996369 — Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
· Phase 3
· completed
NCT04162769 — A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
· Phase 2
· completed
NCT04043455 — Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant
· Phase 2
· terminated
NCT03945188 — Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arena Pharmaceuticals
Last refreshed: 11 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072953.